Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.58 ▼ -0.02
(-3.37%)
MKT CAP: $177.4M • VOL: 5.38M
52W L $1 52W H $3
IVVD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $53.4M | $25.4M | $0 |
| YoY Revenue Growth % | +110.5% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$55.6M | -$176.9M | -$212.8M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$52.5M | -$169.9M | -$198.6M |
| EBITDA (Normalized) | -$55.4M | -$176.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$58.1M | -$170.5M | -$173.2M |
| Capital Expenditures (CapEx) | $155.0K | $140.0K | — |
| Free Cash Flow (FCF) | -$58.3M | -$170.6M | -$173.2M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $226.7M | $69.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $241.5M | $67.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IVVD.